Ozempic Activates Hunger Neurons to Sustain Weight Loss
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Yale researchers found that semaglutide activates AgRP hunger neurons rather than suppressing them, reversing a long-standing assumption about how GLP-1 drugs like Ozempic produce sustained weight loss of 10-15% or more.
- AgRP neurons were required for the drugs' lasting effects — in mice genetically engineered to lack them, GLP-1 drugs could no longer sustain weight loss.
- Mateus d'Ávila, a Ph.D. candidate in Tamas Horvath's lab at Yale School of Medicine, led the study published in PNAS (2026, Vol. 123, Issue 32, DOI: 10.1073/pnas.2614476123).
- The experiments combined body weight, food consumption, metabolism, and energy expenditure tracking with genetic silencing of AgRP neurons, alongside electron microscopy, molecular biology, and electrophysiology.
- During the calorie deficit created by GLP-1 treatment, AgRP neurons appear to be recruited to help coordinate fat loss rather than working against it as previously believed.
- The findings are in mice so far, and researchers note further work is needed to determine whether the same mechanism operates in humans.
Why it matters: Researchers say identifying a previously unrecognized neural mechanism could open an avenue for designing next-generation obesity therapies that are more effective or have fewer side effects than current GLP-1 drugs — a direct implication stated by the Yale team, with the caveat that human confirmation is still pending.
Ask SkimNews
